SandraLSilbermanMD

PubMed

• Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refra...
  Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman, Eunice S Wang, Amer M Zeidan> ;Annals of Hematology. 2023 Nov 1
• 4 citations
  A role for the androgen receptor in the treatment of male breast cancer
  Jason Zhu, Carter Thomas Davis, Sandra Silberman, Neil L. Spector, Tian Zhang> ;Critical Reviews in Oncology/hematology. 2016 Feb 1
• Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB).
  Saulnier Sholler GL, Eslin D, Roberts WD, Kaplan J, Bergendahl G, Ashikaga T, Higgins T, Lenox S, Silberman S, Ferguson W> ;J. Clin. Oncol.. 2011-05-20
• A phase I study of TPI 287, a novel taxane, administered weekly in patients with advanced cancer.
  Silberman S, Hwang JH, Marshall JL, Ahmed T, Basche M, Cohn AL, Modiano MR, Tapolsky G, Yancik S, Pugliese L> ;J. Clin. Oncol.. 2008-05-20
• A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer.
  Modiano MR, Plezia P, Basche M, Cohn AL, Baram Y, Tapolsky G, Yancik S, Pugliese L, Silberman S> ;J. Clin. Oncol.. 2008-05-20
• TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC).
  Gross M, Pendergrass K, Leitner S, Leichman G, Pugliese L, Silberman S> ;J. Clin. Oncol.. 2008-05-20
• E7389, a novel anti-tubulin, in patients with refractory breast cancer.
  Forero JB, Heiskala MK, Meneses N, Chandrawansa K, Fang F, Shapiro G, Fields SZ, Silberman S, Vahdat L> ;J. Clin. Oncol.. 2006-06-20
• A phase II study of a novel anti-tubulin, E7389, in patients with advanced non-small cell lung cancer (NSCLC).
  Das A, Spira A, Iannotti N, Savin M, Zang E, Datta K, Shapiro G, Patturajan M, Silberman S> ;J. Clin. Oncol.. 2006-06-20
• Pharmacokinetics (PK) of E7389, a Halichondrin B analog with novel anti-tubulin activity: Results of two phase I studies with different schedules of administration.
  Wong N, Desjardins C, Silberman S, Lewis M> ;J. Clin. Oncol.. 2005-06-01
• Phase I study of E7389 administered by 1 hour infusion every 21 days.
  Rubin EH, Rosen L, Rajeev V, Wiggins L, Sicam J, Silberman S, Shapiro G> ;J. Clin. Oncol.. 2005-06-01
• Dose escalation and pharmacokinetic (pk) study of E 7389, a microtubule-binding drug in patients (pts) with advanced solid tumors.
  Desai KK, Goel S, Mita A, Silberman S, Sicam J, Woeppel S, Macapinlac M, Berg K, Rowinski E, Mani S> ;J. Clin. Oncol.. 2005-06-01
• Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines.
  Agoulnik S, Kuznetsov G, Tendyke K, Parent LA, Marsh JP, Twine N, Renshaw FG, Silberman S, Littlefield BA> ;J. Clin. Oncol.. 2005-06-01
• 143 citations
  Phase II study of imatinib in patients with small cell lung cancer.
  Bruce E. Johnson, Thomas Fischer, Berthold Fischer, David Dunlop, Danny Rischin, Sandra Silberman, Mildred Ortu Kowalski, Deanne Sayles, Sasa Dimitrijevic, Christopher...> ;Clinical Cancer Research. 2003 Dec 1
• 1689 citations
  Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
  Michael Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura McGreevey, Chang Jie Chen, Annick D. Van den...> ;Journal of Clinical Oncology. 2003 Dec 1
• 375 citations
  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
  Sigrid Stroobants, J. Goeminne, M. Seegers, Sasa Dimitrijevic, Patrick Dupont, Johan Nuyts, M. Martens, B. van den Borne, P. Cole, Raf Sciot, Herlinde Dumez, Sandra Si...> ;European Journal of Cancer. 2003 Sep 1
• 23 citations
  Imatinib: a targeted clinical drug development.
  Renaud Capdeville, Sandra Silberman> ;Seminars in Hematology. 2003 Apr 1
• 430 citations
  Management of malignant gastrointestinal stromal tumours.
  Heikki Joensuu, Christopher D.M. Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter J. Roberts, George D. Demetri> ;The Lancet. Oncology. 2002 Nov 1
• 28 citations
  Imatinib: the first 3 years.
  Renaud Capdeville, Sandra Silberman, Sasa Dimitrijevic> ;European Journal of Cancer. 2002 Sep 1
• 479 citations
  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
  Jane F. Apperley, Martine Gardembas, Junia V. Melo, Robin Russell-Jones, Barbara J. Bain, E. Joanna Baxter, Andrew Chase, Judith M. Chessells, Marie Colombat, Claire E...> ;The New England Journal of Medicine. 2002 Aug 15
• 3155 citations
  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
  George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton L. Eisenberg, Peter J. Roberts, Michael Heinrich, David A. Tuveson, Samuel...> ;The New England Journal of Medicine. 2002 Aug 15
• 936 citations
  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
  Allan T. van Oosterom, Ian Judson, Jaap Verweij, Sigrid Stroobants, Eugenio Donato di Paola, Sasa Dimitrijevic, Marc Martens, Andrew Webb, Raf Sciot, Martine Van Glabb...> ;Lancet. 2001 Oct 27
• 832 citations
  Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
  Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Jinee Rizzo, Lisa A. Hammond, Chris H. Takimoto, S. Gail Eckhardt, Anthony W. Tolcher, Carolyn D. Britten, Louis Denis...> ;Journal of Clinical Oncology. 2001 Jul 1
• 1438 citations
  Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
  Heikki Joensuu, Peter J. Roberts, Maarit Sarlomo-Rikala, Leif C. Andersson, Pekka Tervahartiala, David A. Tuveson, Sandra Silberman, Renaud Capdeville, Sasa Dimitrijev...> ;The New England Journal of Medicine. 2001 Apr 5
• Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
  Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL> ;J. Clin. Oncol.. 1999-01-01
• 21 citations
  The Effect of Tenidap on Cytokines, Acute-Phase Proteins, and Virus Load in Human Immunodeficiency Virus (HIV)-Infected Patients: Correlation between Plasma HIV-1 RNA ...
  Bruce J. Dezube, Michael M. Lederman, Beryl Chapman, Daniel L. Georges, Alex L. Dogon, Phillipa Mudido, Joann Reis-Lishing, Shu Lin Cheng, Sandra L. Silberman, Clyde S...> ;The Journal of Infectious Diseases. 1997 Sep 1
• Join now to see all

Abstracts/Posters

• Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
  Sandra L Silberman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019